Meina Tao Tang
Overview
Explore the profile of Meina Tao Tang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
298
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang W, Scalori A, Fuh F, McBride J, She G, Kierkus J, et al.
Inflamm Bowel Dis
. 2022 Apr;
28(10):e143.
PMID: 35366308
No abstract available.
2.
Zhang W, Scalori A, Fuh F, McBride J, She G, Kierkus J, et al.
Inflamm Bowel Dis
. 2021 Dec;
28(9):1348-1356.
PMID: 34849918
Background: Etrolizumab, a humanized anti-β7 antibody, has not been studied in children. Here, we evaluate the pharmacokinetics, pharmacodynamics, and safety of etrolizumab in children with inflammatory bowel disease. Methods: Patients...
3.
Danese S, Colombel J, Lukas M, Gisbert J, DHaens G, Hayee B, et al.
Lancet Gastroenterol Hepatol
. 2021 Nov;
7(2):118-127.
PMID: 34798038
Background: Etrolizumab is a gut-targeted anti-β7 integrin monoclonal antibody. In a previous phase 2 induction study, etrolizumab significantly improved clinical remission versus placebo in patients with moderately to severely active...
4.
Zhang W, Tyrrell H, Ding H, Pulley J, Boruvka A, Erickson R, et al.
Adv Ther
. 2021 Mar;
38(5):2418-2434.
PMID: 33778929
Introduction: Etrolizumab is a novel, dual-action anti-β7 integrin antibody studied in phase 3 trials in patients with inflammatory bowel disease. An autoinjector (AI) is being developed in parallel to complement...
5.
Tyrrell H, Ravanello R, Pulley J, Tang M, Zhang W, Abouhossein M, et al.
Adv Ther
. 2021 Mar;
38(5):2406-2417.
PMID: 33778928
Introduction: Etrolizumab is a novel, dual-action, anti-β7 integrin antibody in development for patients with moderate to severe ulcerative colitis or Crohn's disease. Phase 3 studies use a prefilled syringe (PFS)...
6.
Hinton P, Xiong J, Johlfs M, Tang M, Keller S, Tsurushita N
J Immunol
. 2005 Dec;
176(1):346-56.
PMID: 16365427
The serum half-life of IgG Abs is regulated by the neonatal Fc receptor (FcRn). By binding to FcRn in endosomes, IgG Abs are salvaged from lysosomal degradation and recycled to...
7.
Hinton P, Johlfs M, Xiong J, Hanestad K, Ong K, Bullock C, et al.
J Biol Chem
. 2003 Dec;
279(8):6213-6.
PMID: 14699147
The neonatal Fc receptor (FcRn) plays an important role in regulating the serum half-lives of IgG antibodies. A correlation has been established between the pH-dependent binding affinity of IgG antibodies...
8.
Nussenblatt R, Thompson D, Li Z, Chao Chan C, Peterson J, Robinson R, et al.
J Autoimmun
. 2003 Nov;
21(3):283-93.
PMID: 14599854
Therapy for severe uveitis is frequently long-term immunosuppression using systemic corticosteroids and cytotoxic agents, but side effects make long-term therapy difficult. A long-term (>4 year) Phase I/II single armed interventional...